Instalab
logoInstalab

NMR Lipoprofile

Blood Test
See the particle-level heart and metabolic risk that a standard cholesterol test can quietly leave behind.
4.9 (4,085 reviews)
Tested by Quest or Access Medical
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers · 8-hour fast required
Get results
Explained with clear next steps, no medical jargon

Should you take a NMR Lipoprofile test?

This test is most useful if any of these apply to you.

Told Your Cholesterol Is Fine
You were told your cholesterol is normal, but you want to know if your particle count tells a different story.
Carrying Weight Around the Middle
Belly weight can hide an insulin-resistant pattern this panel catches before your blood sugar starts to move.
Managing Diabetes or Prediabetes
You manage prediabetes or diabetes, where cholesterol often looks fine while particle risk quietly climbs.
Heart Disease Runs in Your Family
Early heart disease in your family means you want to find hidden particle risk a basic panel can miss.

8 Biomarkers Included

About NMR Lipoprofile

Your cholesterol number can look reassuring while the traffic inside your arteries tells a different story. Cholesterol is the cargo, but it is the particles carrying that cargo that lodge in artery walls and start plaque.

This panel uses a lab technique called nuclear magnetic resonance (NMR) to count those particles and measure their size. Read together, the results can flag two things a basic cholesterol test often cannot: how many dangerous particles you actually carry, and whether an early insulin-resistant pattern is forming underneath.

What This Panel Reveals

The core idea is particle count versus cholesterol content. The number of LDL particles (LDL-P) is the tally of cholesterol-carrying particles most able to enter your artery walls. In large studies, cardiovascular risk rose about 28% for each standard step up in this particle count. When particle number is high but LDL cholesterol looks normal, emerging evidence suggests the particle count is the more reliable warning.

The panel also profiles the size and type of those particles. A high count of small, dense LDL particles (small LDL-P) and a smaller average LDL size point toward an insulin-resistant pattern, though size on its own adds little once particle number is known. Each standard step up in small particle count was tied to about 12% higher risk in pooled data.

A separate group of markers captures triglyceride-rich risk. The count of large, triglyceride-carrying particles from your liver (large VLDL-P) and their average size (VLDL size) are closely tied to remnant cholesterol, the leftover particles that keep driving artery disease even after LDL is lowered. These markers rise early as metabolism shifts, often before a routine panel looks clearly abnormal.

Finally, the HDL and insulin-resistance markers round out the picture. HDL particle number (HDL-P) and HDL size describe your cholesterol-clearing side, though the relationship between HDL particle size and protection is complex and still being worked out in research, with newer studies pointing toward smaller and medium particles rather than large ones. The Lipoprotein Insulin Resistance score (LP-IR) combines six of these particle measures into one number that summarizes insulin resistance, and it correlated moderately with a standard research measure of insulin resistance.

How to Read Your Results Together

The value of this panel is in the combinations, not any single line. The most useful signal is discordance, meaning your particle count and your cholesterol disagree. In one large cohort, when the two numbers diverged, cardiovascular risk rose about 45% for each standard step up in particle number while the cholesterol number showed no meaningful link.

PatternWhat It Suggests
High LDL-P with normal or low LDL cholesterolHidden particle risk. Your cholesterol looks fine, but the particle count is the number to act on.
High small LDL-P, high large VLDL-P, low HDL-P, high LP-IRAn insulin-resistant pattern. The driver is more likely metabolic than dietary.
High LDL-P with normal LP-IR and normal triglyceride-rich particlesA cholesterol-driven pattern. Focus on lowering particle burden directly.
Normal LDL-P but rising large VLDL-P and LP-IRAn early metabolic shift worth tracking, even with an unremarkable standard panel.

What to Do with Your Results

If your particle count is high, the most useful next step is a protein called apolipoprotein B (apoB), which counts artery-clogging particles directly and is the marker most expert groups now favor for confirming particle burden. Pair it once with a particle called lipoprotein(a), or Lp(a), an inherited risk factor this panel does not capture well. Together these sharpen a high LDL-P finding into a clear action plan.

If the insulin-resistant pattern dominates, add fasting insulin and HbA1c, a three-month blood sugar average, to see how far the metabolic shift has progressed. An LP-IR score can rise years before fasting glucose moves, so a high score is a reason to tighten diet, activity, and weight around the middle now rather than wait.

For tracking, use the same laboratory each time, since NMR particle results are not fully standardized across providers. Retest three to six months after any meaningful change to confirm the direction is what you wanted. Particle counts often improve more slowly than cholesterol on treatment, so give changes time to show.

When Results Can Be Misleading

A few conditions shift several markers at once. Eating before the draw inflates triglyceride-rich particles, so large VLDL-P, VLDL size, and LP-IR can all read falsely high after a meal. Because subclass results differ between NMR platforms, values from two different labs are not always interchangeable. And because Lp(a) is not measured well here, a normal panel does not rule out that inherited risk.

Frequently Asked Questions

References

12 studies
  1. J. Otvos, S. Mora, I. Shalaurova, P. GreenlandJournal of Clinical Lipidology2011
  2. J. a. Quesada, V. Bertomeu-gonzález, D. Orozco-beltrán, a. Cordero, V. Gil-guillén, a. López-pineda, Rauf Nouni-garcía, C. Carratalá-munueraClínica E Investigación En Arteriosclerosis2023
  3. S. Parish, a. Offer, R. Clarke, J. Hopewell, M. Hill, J. Otvos, J. Armitage, R. CollinsCirculation2012
  4. Irina Shalaurova, Margery a. Connelly, W. Timothy Garvey, James D. OtvosMetabolic Syndrome and Related Disorders2014
  5. R. Mackey, S. Mora, a. Bertoni, C. Wassel, M. Carnethon, C. Sibley, D. GoffDiabetes Care2015